Outset Medical (OM) Q4 2025 earnings review
Profitability Focus Eclipses Growth Stagnation
Outset Medical delivered a mixed Q4. The 'commercial transformation' narrative hit a wall with Revenue declining 2% YoY to $28.9M, erasing the momentum seen in H1. However, the bottom-line execution was stellar: Non-GAAP Gross Margin surged to 42.9% (+430 bps YoY) and operating expenses fell 8%, significantly narrowing losses. The company is successfully pivoting from 'growth at all costs' to efficiency, but the lack of top-line expansion—and a soft FY26 growth guide of 5-9%—raises questions about underlying demand.
🐂 Bull Case
Gross margin expansion is real and accelerating. Product gross margin hit 50.7% in Q4 (vs 44.0% a year ago). This validates the cost-down initiatives and proves the hardware economics can support profitability.
Cash burn has been tamed. Ending cash of $173M provides a substantial runway, especially with FY26 guidance implying continued discipline. The existential risk of running out of cash before breakeven has largely dissipated.
🐻 Bear Case
A major red flag: Recurring revenue (consumables/services) actually fell to $22.5M in Q4 from $23.7M a year ago. For a 'razor/razorblade' model, a drop in recurring revenue suggests utilization issues or inventory destocking at customers.
Product revenue dropped 5% YoY. FY26 guidance for 5-9% growth suggests the 'high growth' phase is over or paused. The Q2 revenue peak of $31.4M now looks like an outlier rather than a trend.
⚖️ Verdict: ⚪
Neutral. The operational discipline is impressive, and the margin improvement is investment-grade. However, a medtech company with shrinking revenues and declining recurring revenue in Q4 faces a valuation ceiling until growth reignites.
Key Themes
Recurring Revenue Unexpectedly Drops
In a surprising reversal, recurring revenue (the stable engine of the business) fell 5% YoY to $22.5M in Q4. This contradicts the narrative of a growing installed base. While ordering timing can be volatile, a year-over-year decline in the recurring line is a significant concern for the long-term model.
Product Gross Margin Crosses 50%
Outset achieved a milestone 50.7% Product Gross Margin in Q4, up dramatically from 44.0% in 24Q4. This was driven by manufacturing efficiencies and cost reductions. Sustaining product margins above 50% is critical for the company to eventually reach GAAP profitability.
Next-Generation Tablo Clearance
The company received FDA clearance for its next-gen Tablo platform, featuring enterprise-level cybersecurity and connectivity. Launch is expected in Q2 2026. This product cycle could be the catalyst needed to re-accelerate console placements, which have stagnated.
Product Revenue Decay
Product (Console) revenue fell to $19.9M, a 5% decline YoY. Despite the 'commercial transformation' touted in mid-2025, capital equipment sales are not gaining traction. This creates a downstream problem: fewer new consoles placed today means lower recurring revenue growth tomorrow.
Cash Burn Reduction
Full year net cash used in operations dropped to $46M in 2025, down from $116M in 2024. This massive improvement reflects the aggressive opex cuts (Operating Expenses down $38M YoY). The company has successfully right-sized its cost structure to its current revenue reality.
Other KPIs
Stable. The balance is sufficient to fund operations for several years at the current reduced burn rate ($46M FY25 burn). This removes the immediate overhang of a dilutive capital raise.
Improved from -$25.6M in 24Q4. The loss is narrowing primarily due to margin expansion and expense control rather than revenue growth.
Accelerating. Up significantly from 17.8% in 24Q4. As the installed base ages, service efficiency is becoming a genuine profit contributor rather than a drag.
Guidance
Decelerating/Stable. Implies 5% to 9% growth. While technically an acceleration over Q4's negative print, it represents a 'low growth' profile for a company at this stage of market penetration. It suggests no V-shaped recovery in demand.
Stable/Accelerating. Continuation of the strong exit velocity from 2025 (42.9% in Q4). Management is banking on mix shift and manufacturing efficiencies to hold these gains.
Key Questions
Recurring Revenue Drop
Recurring revenue fell from $23.7M in 24Q4 to $22.5M in 25Q4. Is this due to customer churn, lower utilization per console, or inventory destocking? This metric should be growing if the installed base is growing.
Next Gen Launch Impact
With the Next Gen Tablo launching in Q2, should we expect initial pressure on Product Gross Margins due to manufacturing ramp-up, or will it be accretive immediately?
Service Revenue Disconnect
Service revenue grew 6% while Product revenue fell 5%. Are you seeing longer sales cycles for capital equipment, and does the FY26 guidance assume a rebound in console placements?